The EMA warns of products being sold as dendritic cell therapies with little evidence, but high health risks, in the European ...

Insilico Medicine has completed a Series E round, raising $110m to progress the development of its pipeline of drugs and AI ...

The EC has approved Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic, Rxulti (brexpiprazole), for treating ...

The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...

Boehringer Ingelheim and Sweden-based Salipro Biotech have entered a research and licence agreement for drug targets' ...

Atsena Therapeutics has received fast track designation from the FDA for ATSN-201, aimed at treating X-linked retinoschisis ...

Vivace Therapeutics has closed $35m in a Series D financing round to support the clinical development of its cancer drug ...

The role of AI in supply chain management proved to be the focal issue at the recent 2025 Clinical Trial Supply Europe ...

Entos Pharmaceuticals has announced an investment of C$62m ($43.05m) from the governments of Canada and Alberta for an R&D facility.

Emergent has entered a strategic financial investment agreement with Swiss Rockets to support the latter’s biotech portfolio.

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.